Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study

• Published in: PloS one 2014-05, Vol.9 (5), p.e95897-e95897
• Main Authors: Chen, Xiaofeng, Zhu, Quan, Liu, Yiqian, Liu, Ping, Yin, Yongmei, Guo, Renhua, Lu, Kaihua, Gu, Yanhong, Liu, Lianke, Wang, Jinghua, Wang, Zhaoxia, Røe, Oluf Dimitri, Shu, Yongqian, Zhu, Lingjun
• Format: Article
• Language: English
• Subjects: Acne; Aged; Analysis; Antineoplastic Agents - therapeutic use; Binding sites; Cancer; Cancer research; Carcinoma, Non-Small-Cell Lung - drug therapy; Care and treatment; Chemotherapy; China; Crown Ethers - therapeutic use; Development and progression; Diarrhea; Disease-Free Survival; Drug dosages; Enzyme inhibitors; Epidermal growth factor; Epidermal growth factor receptors; Exanthema; Hospitals; Humans; Kaplan-Meier Estimate; Kinases; Lung cancer; Lung diseases; Medical prognosis; Medical research; Medicine; Medicine and Health Sciences; Middle Aged; Mutation; Non-small cell lung cancer; Non-small cell lung carcinoma; Oncology; Patients; Physical Sciences; Protein-tyrosine kinase; Quinazolines - therapeutic use; Receptor, Epidermal Growth Factor - antagonists & inhibitors; Research and Analysis Methods; Retrospective Studies; Small cell lung carcinoma; Solid tumors; Studies; Survival; Treatment Outcome; Tumors; Tyrosine
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0095897

Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with preclinical and clinical activity in non-small cell lung cancer (NSCLC). This retrospective analysis was performed to assess the efficacy of icotinib on patients with non-small-cell lung cancer (NSCLC). 82 consecutive patients treated with icotinib as first (n = 24) or second/third line (n = 58) treatment at three hospitals in Nanjing were enrolled into our retrospective research. The Response Evaluation Criteria in Solid Tumors (RECIST) was used to evaluate the tumor responses and the progression-free survival (PFS) and overall survival (OS) was evaluated by the Kaplan-Meier method. Median PFS was 4.0 months (95% CI 2.311-5.689). Median OS was 11.0 months (95% CI 8.537-13.463) in this cohort. Median PFS for first and second/third line were 7.0 months (95% CI 2.151-11.8) and 3.0 months (95% CI 1.042-4.958), respectively. Median OS for first and second/third line were 13.0 months (95% CI 10.305-15.695) and 10.0 months (95% CI 7.295-12.70), respectively. In patients with EGFR mutation (n = 19), icotinib significantly reduced the risk of progression (HR 0.36, 95% CI 0.18-0.70, p = 0.003) and death (HR 0.10, 95% CI 0.02-0.42, p = 0.002) compared with those EGFR status unknown (n = 63). The most common adverse events were acne-like rash (39.0%) and diarrhea (20.7%). Icotinib is active in the treatment of patients with NSCLC both in first or second/third line, especially in those patients harbouring EGFR mutations, with an acceptable adverse event profile.